Belite Bio, Inc. ADR (BLTE) Q2 2026 Earnings Report

Overall the call conveyed substantial positive progress: NDA acceptance with priority review and a clear PDUFA date, supportive Phase 3 QAF data, strong cash balance ($780M), a pediatric program, and high patient compliance. Counterbalancing these positives are materially higher R&D and SG&A expenses, a widening net loss, a confidential one‑time royalty payment, limited disclosure on manufacturing inspection status, and a delayed GA interim readout. The positives (regulatory momentum, strong efficacy signal, and financial runway) outweigh the operational and expense-related concerns.

On the Q2 2026 call management confirmed FDA acceptance of the tinlarebant NDA with priority review and a PDUFA date of February 12, 2027, highlighted Phase 3 Dragon data presented at four conferences in four countries (ASRS data showing ~2% QAF decrease at month 25 with tinlarebant vs ~20% QAF increase on placebo), said Dragon 2 is primarily a Japan/PMDA study, and outlined financials: Q2 R&D $18.2M (non‑GAAP ex‑SBC $17.2M) vs $11.0M/$8.6M year‑ago, SG&A $16.7M (non‑GAAP $10.9M) vs $6.5M/$1.3M, GAAP net loss $28.4M (non‑GAAP net loss $21.6M) vs $16.3M/$8.7M, and $780M in cash/cash equivalents/T‑bills providing a runway to commercialize after potential approval; other guidance included a pediatric PIP study in London for ages 3–11, >90% dosing compliance at 24 months, expectation of a priority review voucher if approved, a GA interim readout likely in Q1 2027 (after the PDUFA period), a planned Japan submission ~3 months after U.S. approval, and a European filing to follow post‑U.S. approval.